Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical company focused on developing therapies for rare diseases. The company is known for its innovative approach to addressing unmet medical needs. Insmed's competitors include other biotech firms that specialize in rare diseases, such as Vertex Pharmaceuticals and BioMarin Pharmaceutical.
On February 19, 2026, Stifel Nicolaus set a price target of $205 for INSM, suggesting a potential upside of 28.22% from the stock's price of $159.88 at the time. This adjustment from a previous target of $212 reflects a strategic reassessment of the company's prospects. The stock is currently trading at $161, showing a 6.54% increase with a recent price change of $9.89.
Insmed's Q4 2025 earnings call provided valuable insights into the company's financial health and strategic plans. The call likely covered key financial metrics such as revenue and profit margins, which are crucial for understanding the company's performance. Investors and stakeholders closely monitor these earnings calls for updates on Insmed's operations and future outlook.
The stock has shown significant volatility, with a daily range between $147.26 and $163.14. Over the past year, INSM has reached a high of $212.75 and a low of $60.40, indicating substantial price fluctuations. The company's market capitalization is approximately $34.34 billion, with a trading volume of 4,921,823 shares, reflecting active investor interest.
